86 related articles for article (PubMed ID: 19549713)
1. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms.
Ma BB; Hui EP; Wong SC; Tung SY; Yuen KK; King A; Chan SL; Leung SF; Kam MK; Yu BK; Zee B; Chan AT
Ann Oncol; 2009 Nov; 20(11):1854-9. PubMed ID: 19549713
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
[TBL] [Abstract][Full Text] [Related]
3. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
4. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
5. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
[TBL] [Abstract][Full Text] [Related]
8. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
10. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Figg WD; Chau CH; Madan RA; Gulley JL; Gao R; Sissung TM; Spencer S; Beatson M; Aragon-Ching J; Steinberg SM; Dahut WL
Clin Genitourin Cancer; 2013 Sep; 11(3):229-37. PubMed ID: 23684781
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
13. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.
Benzeid R; Gihbid A; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; El Benna N; Filali Maltouf A; Attaleb M; Chaoui I; Khyatti M; El Mzibri M
Asian Pac J Cancer Prev; 2023 Jan; 24(1):93-99. PubMed ID: 36708557
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
15. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
16. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
[TBL] [Abstract][Full Text] [Related]
17. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
[TBL] [Abstract][Full Text] [Related]
19. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
[TBL] [Abstract][Full Text] [Related]
20. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma.
Yang ZH; Dai Q; Kong XL; Yang WL; Zhang L
Mol Carcinog; 2009 Mar; 48(3):196-201. PubMed ID: 18615480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]